Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 1;43:156. doi: 10.1186/s13046-024-03083-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Fzd7-KD and ILK inhibition sensitize to platinum treatment. A-C Boxplot and ROC curve of ILK (A), Fzd7 (B), and ILK-Fzd7 combination (C) involved in platinum resistance using the RFS at 6 months cohort from the ROC plotter for OC (Affymetrix ID: 201234_s_at (ILK) and 203705_s_at (Fzd7), respectively). ROC curve analysis shows the sensitivity and specificity of ILK and Fzd7 in predicting the patient response to treatment (P = 7.5e-04, P = 2.4e-03, and P = 1.1e-03, respectively). D-F PFS curves for ILK (D), Fzd7 (E), and ILK in combination with Fzd7 (F) mRNA expression in HGSOC patients (stage: 3 + 4, grade: 3) following platinum/taxane therapy generated using the KM plotter (HR = 1.59, P = 0.011; HR = 1.59, P = 0.0067; and HR = 1.5, P = 0.015, respectively). G WB for p-ILK^Ser246, ILK, p-AKT^Ser473, AKT, and GAPDH in HGSOC platinum (S) PEA1 and platinum (R) PEA2 cells (left panel). Densitometry quantifies p-ILK^Ser246/ILK and p-AKT^Ser473/AKT ratio (right panel) (N = 3; **P < 0.01 and ***P < 0.001). H WB for A-β-catenin, Fzd7, and GAPDH in PEA1 and PEA2 cells (left panel). Densitometry quantifies A-β-catenin and Fzd7 expression levels (right panel) (N = 3; **P < 0.01 and ****P < 0.0001). I Representative phase contrast images of OVCAR-3 cells growing as spheroids and treated with DMSO, carboplatin (double IC₅₀), cpd-22 (0.5 μM) or combination (right panel). Average number of spheroid count (> 50 μm in diameter) (upper-left panel) and CCK-8 quantification (lower-left panel) (N = 3; **P < 0.01, ***P < 0.001, ****P < 0.0001). J Clonogenic assay of OVCAR-3 cells treated with DMSO, carboplatin (IC₅₀), cpd-22 (0.5 μM) or combination. Representative images of single-cell clone proliferation, stained with crystal violet (left panel) and quantification (right panel) (N = 3; **P < 0.01, ***P < 0.001, ****P < 0.0001). K Representative phase contrast images of shCtr vs shFzd7 (clone #2) OVCAR-3 cells growing as spheroids and treated with carboplatin (double IC₅₀) (left panel). Average number of spheroid count (> 50 μm in diameter) (upper-right panel) and CCK-8 quantification (lower-right panel) (N = 3; **P < 0.01 and ****P < 0.0001). L Clonogenic assay of shCtr vs shFzd7 (clone #2) OVCAR-3 cells treated with carboplatin (IC₅₀). Representative images of single-cell clone proliferation, stained with crystal violet (left panel) and quantification (right panel) (N = 3; **P < 0.01 and ****P < 0.0001)